. Author manuscript; available in PMC: 2013 Jul 29.

Published in final edited form as: Schizophr Res. 2009 Apr 7;111(0):167–173. doi: 10.1016/j.schres.2009.03.023

Table 1.

Mean (± SD) amplitudes [μV]) of target ERP components N2 (MMN/N2b) and P3b.

	BCAA	Placebo	F	p	η ²
N2 (MMN/N2b) at Fz	0.39 ± 3.49	−1.04 ± 3.01	3.89	.063	.163
N2 (MMN/N2b) at FCz	−0.27 ± 2.85	−2.04 ± 2.70	8.14	.0098	.289
N2 (MMN/N2b) at Cz	−0.91 ± 2.65	−2.26 ± 2.65	5.19	.034	.206
N2 (MMN/N2b) at Pz	−0.67 ± 2.55	−1.02 ± 2.21	0.15	.702	.007

P3 at Fz	2.21 ± 3.34	4.51 ± 5.10	2.70	.116	.118
P3 at FCz	3.57 ± 4.18	6.29 ± 5.07	4.54	.046	.185
P3 at Cz	5.63 ± 4.49	7.44 ± 4.48	1.53	.231	.071
P3 at Pz	10.42 ± 5.54	11.68 ± 4.99	2.39	.138	.107

Significant differences (p<.01) are highlighted; BCAA, branched chain amino acid; MMN, mismatch negativity; η², partial eta-squared.